Merck has invested $125 million in Moderna under a new deal that expands on the 2016 partnership to develop neoantigen based vaccines. This also includes shared antigen mRNA cancer vaccines including mRNA-5671, Moderna's KRAS targeting one. So they won't be acquiring NWBO any time soon.
Market Data 
Markets 
AI
